Rapastinel powder
CAS. NO:117928-94-6
MF.no:C18H31N5O6
Other names:GLYX13;GLYX 13;GLYX-13;Rapastinel;GLYX-13 trifluoroacetate;GLYX 13;Thr-Pro-Pro-Thr-NH2 trifluoroacetate;TPPT-amide trifluoroacetate;BV-102;TPPT-amide
Test Method:HPLC/UV/GC-MS
MOQ & Package: 10g,100g,1kg,5kg,10kg,25kg etc
Customer's rights and interests:Over 10kg, you can enjoy the service of giving away free samples.
Certificate：FDA,ISO,COA, HPLC, MSDS,TDS etc
Lead Time: 1-3 days
Shipping: DHL,Germany DHL,Germany DPD,UPS,USPS,FedEx,EMS,By Air,By Sea,multimodal transport etc
Store & Shelf life; Cool & dry place; 36 months
Company advantages: there are self-built overseas warehouses and third-party overseas warehouses on all continents.
- Product Description
Xi'an Faithful BioTech Co., Ltd: Your Trusted Rapastinel powder Manufacturer & Supplier
Rapastinel powder is a partial agonist targeting the glycine site of N-methyl-D-aspartate receptor (NMDAR). Research has shown that GLYX-13 has a long-lasting antidepressant effect. The Xi'an Faithful BioTech Co., Ltd provide is an optimized amidated tetrapeptide that not only possesses unconventional central activity, but also has the ability to rapidly and effectively inhibit and enhance NMDA receptor-mediated signal transduction. It is currently a popular and powerful cognitive enhancer.
Rapastinel powder Introduction
Rapastinel powder is a novel tetrapeptide (consisting of a chain of four amino acids) that is being developed as a fast acting antidepressant and adjuvant therapy for severe depression (MDD). Its mechanism of action is basically similar to that of general puzzle ingredients, mostly non competitive antagonists of the same receptor family, but the receptors that GLYX-13 acts on are different. GLYX-13 acts as a partial agonist on NMDA receptors, particularly at the glycine site. Research has shown that GLYX-13 powder directly enhances NMDA receptor activity in the central nervous system through a novel structural domain independent of glycine co agonist sites, promoting synaptic plasticity and thus producing antidepressant effects. Therefore, it is also believed to rapidly enhance neuroplasticity - the ability of the brain to form new connections and adapt.
Specifications
Item | Specifications | Results |
Appearance | White powder | Conform |
Melting point | 146-150℃ | 148.3-149.2℃ |
lead(Pb) | ≤8PPm | <8ppm |
Arsenic（As） | ≤1PPm | <1PPm |
Iron(Fe) | ≤15PPm | <15PPm |
Residue on ignition | ≤0.1% | 0.08% |
Loss on drying | ≤1.0% | 0.8% |
Assay | 98.0～100.0% | 99.8% |
| Conclusion： | Conform with enterprise specification （USP 41）. |
Why Choose Us?
Professional team: Our members have profound chemical and pharmacological backgrounds, and deeply understand the mechanism and research value of Rapastinel (GLYX-13) as a partial agonist of NMDA receptor.
Quick response: We promise to reply to all your email inquiries within 1 working day.
Complete documentation: A complete set of technical documents including third-party analysis certificates and material safety data sheets can be provided at any time to help you successfully pass the ethics and compliance review.
Solution-oriented: We not only sell products, but also hope to be your partner in solving scientific research problems.
If you are interested in our Rapastinel powder, please leave us a message via email：sales8@faithfulbio.com.
Clinical research progress and application:
Early studies: In phase II clinical trials, GLYX 13 powder showed rapid onset of action, producing antidepressant effects in as little as 2 hours. After a single use, the effect can last for 7 days, and after repeated administration, the clinical effect can be maintained for at least 10 weeks.
Phase III clinical trials: However, the results of Phase III clinical trials (RAP-MD-01, RAP-MD-02, RAP-MD-03) published in 2019 showed no significant differences between the treatment group and the placebo group in terms of primary and key secondary endpoints. The mid-term analysis of the Relapse Prevention Study (RAP-MD-04) also indicated that the primary endpoint could not be achieved.
Clinical application: It has obtained breakthrough drug status and fast track approval qualification from the US FDA to address a large number of post-war syndromes in the United States. In medicine, its initial market application was for the treatment of severe depression, especially for patients with refractory depression who did not respond well to existing antidepressant drugs. At present, its application data is sufficient to support its use as an adjuvant therapy pharmaceutical material for the treatment of various refractory major depressive disorders.
Quality Control:
R&D Results:
Packaging and Transportation:
After-Sales Service:
Qualification Certification:
Transaction Feedback:
Exhibition:
FAQ
Q1. What is Rapastinel?
Rapastinel is a novel experimental compound that was once considered an antidepressant with rapid onset potential. It is a tetrapeptide that works by regulating NMDA receptors, especially the glycine site. Currently, the market positioning of this product is as an auxiliary and standard raw material for the development of new pharmaceutical raw materials.
Q2. What is the basis of its mechanism of action?
GLYX-13 is a partial agonist of NMDA receptors. It does not completely block receptors like some puzzle materials, but rather fine tunes them. This regulation is believed to rapidly promote the neural plasticity of the brain, which is the ability of the brain to form new connections, adapt, and learn, and is considered the basis for its rapid onset antidepressant effect.
Q3. Can I still buy 'Rapastinel powder'?
You may find a list of products selling "Rapastinel powder" or "Rapastinel (GLYX-13)" through our company. However, these products are strictly labeled as "for research purposes only" and are not intended for human use. So in use, we should strictly follow our instructions.
Contact us
On the path of exploring the forefront of neuroscience, pure and reliable GLYX 13 research materials are the key to success. We focus on providing high-purity (>99%) and structurally confirmed Rapastinel powders, committed to providing a solid foundation for your research projects.
If you have any questions about products, technology, or collaboration, our professional team is ready to provide support for you.
Our contact email is: sales8@faithfulbio.com
